23:18 , Apr 20, 2017 |  BC Innovations  |  Product R&D

Selectivity suite

Although the small molecule landscape has been largely defined by protein-binding agents, new classes of compounds are emerging that block the formation of specific proteins at the level of their RNA, redefining what constitutes a...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer MicroRNA-17-92 (miR-17-92) Cell culture and mouse studies suggest inhibiting miR-17-92 could help treat medulloblastoma. In a mouse model of medulloblastoma, miRNAs from the...
07:00 , May 3, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Microarray of modified RNAs to identify therapeutic RNAs against folded RNA targets A microarray displaying a library of modified RNAs could help identify therapeutics...
07:00 , Sep 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Retinoblastoma MicroRNA-17-92 (miR-17-92); miR-17; miR-20 Patient sample and mouse studies suggest inhibiting miRNAs encoded by the miR-17-92 cluster could help treat retinoblastoma. In patient samples,...
08:00 , Feb 28, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity miR-17-92 cluster (including miR-17-5p, miR-17-3p, miR-18, miR-19b, miR-20); retinoblastoma 2 (Rb2/p130) A study in cell culture suggests targeting the...